ValiRx Regulatory News (VAL)

3 November 2014

ValiRx Plc

 ("ValiRx" or "the Company")

Approved Clinical Trial Update

Re: Further Progress with the Trial

("A Phase I/II, dose escalation study to assess the safety and tolerability of VAL201 in patients with locally

advanced or metastatic prostate cancer and other advanced solid tumours.")

ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that in accordance with regulation and guidelines on the transparency of clinical trials, full details of the VAL201 trial are available on the United States of America's National Institutes of Health searchable database www.clinicaltrials.gov.

The posting of the trial information in such a forum is a legal requirement that has to be fulfilled following CTA approval and immediately before application of the trial substance to human beings. As this is the first trial listing where ValiRx is the "Sponsor" it is an exciting progression in the continued development of the human chapter of VAL201. The preliminary outcomes from the first cohort are anticipated during Q1 2015.

Dr Satu Vainikka, CEO of ValiRx, commented: "I am pleased that the trial is progressing as announced and the whole team is delivering according to the schedule in the Company's plan".

- ENDS -

For more information, please contact:-

Notes to the editor

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiFinn is the biomarkers and diagnostic development division

2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.